Biomarker Lens

Biomarkers · Chemical

Fentanyl, Urine

Understand what Fentanyl, Urine signals

Primary unit
ng/mg creat
LOINC codes
10975-1, 11075-9, 12382-8, 12602-9, 15372-6, 16249-5, 17395-5, 19328-4, 19346-6, 2161-8, 2756-5, 28073-5, 2965-2, 3394-4, 3508-9, 3637-6, 3681-4, 3725-9, 3780-4, 3831-5, 3887-7, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0, 106132-4, 11052-8, 16114-1, 17719-6, 18322-8, 18338-4, 18355-8, 19570-1, 19611-3, 33339-3, 33507-5, 3415-7, 3755-6, 3774-7, 3875-2, 3937-0, 49753-7, 50542-0, 59680-9, 64125-8, 65807-0, 65808-8, 72768-5, 82524-0, 96059-1, 10976-9, 10998-3, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 73566-2, 86453-8, 95135-0, 9834-3, 87428-9
Commercial laboratory assays
9

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Fentanyl, Urine

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Drug Monitoring Assess Panel, Base, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39989
Specimen
Urine
Fasting
Not stated
LOINC
10975-1, 11075-9, 12382-8, 12602-9, 15372-6, 16249-5, 17395-5, 19328-4, 19346-6, 2161-8, 2756-5, 28073-5, 2965-2, 3394-4, 3508-9, 3637-6, 3681-4, 3725-9, 3780-4, 3831-5, 3887-7, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

A single direct to definitive panel with the ability to identify multiple specific drugs and metabolites across drug classes facilitates enhanced patient care. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39989

Drug Monitoring Assess Panel, Extended, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39992
Specimen
Urine
Fasting
Not stated
LOINC
106132-4, 10975-1, 11052-8, 11075-9, 12382-8, 12602-9, 15372-6, 16114-1, 16249-5, 17395-5, 17719-6, 18322-8, 18338-4, 18355-8, 19328-4, 19346-6, 19570-1, 19611-3, 2161-8, 2756-5, 28073-5, 2965-2, 33339-3, 33507-5, 3394-4, 3415-7, 3508-9, 3637-6, 3681-4, 3725-9, 3755-6, 3774-7, 3780-4, 3831-5, 3875-2, 3887-7, 3937-0, 49753-7, 50542-0, 54247-2, 58714-7, 59589-2, 59680-9, 60677-2, 61422-2, 61425-5, 64125-8, 65807-0, 65808-8, 72768-5, 82524-0, 96059-1, 9835-0

Laboratory assay overview

A single direct to definitive panel with the ability to identify multiple specific drugs and metabolites across drug classes facilitates enhanced patient care. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39992

Drug Monitoring Assess Panel, Plus, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39991
Specimen
Urine
Fasting
Not stated
LOINC
106132-4, 10975-1, 11075-9, 12382-8, 12602-9, 15372-6, 16249-5, 17395-5, 19328-4, 19346-6, 2161-8, 2756-5, 28073-5, 2965-2, 3394-4, 3415-7, 3508-9, 3637-6, 3681-4, 3725-9, 3774-7, 3780-4, 3831-5, 3887-7, 49753-7, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

A single direct to definitive panel with the ability to identify multiple specific drugs and metabolites across drug classes facilitates enhanced patient care. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39991

Drug Monitoring, Opioids Panel, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39012
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 54247-2, 65807-0, 65808-8, 73566-2, 86453-8, 95135-0, 96059-1, 9834-3

Laboratory assay overview

Monitoring of parent compounds and their metabolites in urine. The results of this test are used in specific treatment programs to determine compliance with prescribed dosing schedules.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Buprenorphine<2 ng/mL
Norbuprenorphine<2 ng/mL
Naloxone<2 ng/mL
Fentanyl<0.5 ng/mL
Norfentanyl<0.5 ng/mL
Heroin Metabolite<10 ng/mL
Methadone<100 ng/mL
EDDP<100 ng/mL
Dextromethorphan<20 ng/mL
Dextrorphan<20 ng/mL
Mitragynine<2 ng/mL
Codeine<50 ng/mL
Hydrocodone<50 ng/mL
Hydromorphone<50 ng/mL
Norhydrocodone<50 ng/mL
Morphine<50 ng/mL
Oxycodone<50 ng/mL
Oxymorphone<50 ng/mL
Noroxycodone<50 ng/mL
Tapentadol<50 ng/mL
Nortapentadol<50 ng/mL
Tramadol<100 ng/mL
O-desmethyltramadol<100 ng/mL
View complete laboratory reference notes

Buprenorphine <2 ng/mL Norbuprenorphine <2 ng/mL Naloxone <2 ng/mL Fentanyl <0.5 ng/mL Norfentanyl <0.5 ng/mL Heroin Metabolite <10 ng/mL Methadone <100 ng/mL EDDP <100 ng/mL Dextromethorphan <20 ng/mL Dextrorphan <20 ng/mL Mitragynine <2 ng/mL Codeine <50 ng/mL Hydrocodone <50 ng/mL Hydromorphone <50 ng/mL Norhydrocodone <50 ng/mL Morphine <50 ng/mL Oxycodone <50 ng/mL Oxymorphone <50 ng/mL Noroxycodone <50 ng/mL Tapentadol <50 ng/mL Nortapentadol <50 ng/mL Tramadol <100 ng/mL O-desmethyltramadol <100 ng/mL

Quest Diagnostics test directory, test code 39012

ToxAssure® Flex 15, Urine

Laboratory
Labcorp
Test code
912334
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 912334

ToxAssure® Flex 16, Urine

Laboratory
Labcorp
Test code
912460
Specimen
Urine
Fasting
Not stated
LOINC
87428-9
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 912460

ToxAssure® Flex 23, Urine

Laboratory
Labcorp
Test code
912335
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 912335

ToxAssure® Flex 24, Urine

Laboratory
Labcorp
Test code
912470
Specimen
Urine
Fasting
Not stated
LOINC
87428-9
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 912470

ToxAssure® Flex Fentanyl Confirmation, Urine

Laboratory
Labcorp
Test code
911127
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 911127

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.